Adynovate Phase 3 Efficacy and Safety Data in Children to be Presented

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in it’s entirety here.
Shire will present additional data on the clinical experience of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant Factor VIII (rFVIII) replacement for hemophilia A, during the International Congress of the World Federation of Hemophilia (WFH) in Orlando, Florida. Throughout the Congress, Shire will present more than a dozen scientific updates on the company’s broad portfolio of treatments for bleeding disorders, including ADYNOVATE.